You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial

Citation Tools

Article menu
Clinical/translational cancer immunotherapy
Original research
Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Mei K, Qin S, Chen Z, et al
Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial
Journal for ImmunoTherapy of Cancer 2021;9:e002191. doi: 10.1136/jitc-2020-002191